Cargando…
T cell landscape and dynamics in immunoglobulin light chain amyloidosis before and after daratumumab‐based therapy
Amyloid light‐chain (AL) is characterized by the presence of small, poorly proliferating plasma cell clones with the production and deposition of light chains into tissues. T cell changes within the tumour microenvironment in AL are poorly understood. By sequencing at a single‐cell level of CD3(+) T...
Autores principales: | Wang, Yujia, Xu, Lushuang, Zhao, Weijia, Chen, Xiaojie, Wen, Lei, Duan, Wenbing, Yu, Xiao‐Juan, De Zhou, Fu‐, Liu, Yang, Hao, Jie, Huang, Xiaojun, Lu, Jin, Ge, Qing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8630449/ https://www.ncbi.nlm.nih.gov/pubmed/34845849 http://dx.doi.org/10.1002/ctm2.582 |
Ejemplares similares
-
Daratumumab in the Treatment of Light-Chain (AL) Amyloidosis
por: Palladini, Giovanni, et al.
Publicado: (2021) -
Systemic light chain amyloidosis myopathy responsive to daratumumab monotherapy
por: Chitimus, Diana Maria, et al.
Publicado: (2022) -
Daratumumab plus CyBorD for patients with newly diagnosed light chain (AL) amyloidosis
por: Theodorakakou, Foteini, et al.
Publicado: (2021) -
Localized Immunoglobulin Light-Chain Amyloidosis of the Ulnar Nerve
por: Morisaki, Shinsuke, et al.
Publicado: (2021) -
Alterations of the gut microbiota in patients with immunoglobulin light chain amyloidosis
por: Yan, Jipeng, et al.
Publicado: (2022)